Tumor necrosis factor- inhibitor-associated psoriasis: Facts and hypotheses
Feng Luo,Yung-Heng Lee,Wu-kai Ma,Su-Boon Yong,Xue-ming Yao,James Cheng-Chung Wei
DOI: https://doi.org/10.1111/1756-185X.14661
2023-01-01
International Journal of Rheumatic Diseases
Abstract:Rheumatic diseases are chronic systemic autoimmune diseases that mainly affect joints, bones, muscles, blood vessels, and related connective tissues.1 An example is psoriatic diseases which affect the skin as well as joints and internal organs. Globally, over 125 million people have psoriasis.2 The incidence of psoriasis in the European and American populations is 2%–3%,3 and 0.2% in the Asian population.4 The pathology of psoriasis involves infiltration of inflammatory cells into the skin and excessive proliferation of keratinocytes, resulting in well-defined erythematous degeneration.2 Psoriasis impacts quality of life and is associated with many comorbidities.5-8 The most common clinical subtype of psoriasis is chronic plaque psoriasis vulgaris; other subtypes include gutta, pustular, erythrodermic, and arthropathic psoriasis.9 Psoriasis affects approximately 10% of patients with non-radiographic axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS).10 Patients with concomitant psoriasis and axSpA and peripheral joint involvement, have possibly a more severe axSpA disease course more frequently than axSpA patients without psoriasis.11 Consequently, psoriasis related to immune-mediated inflammatory disease and medication have not been sufficiently explored. Notably, the treatment of psoriasis has changed substantially over the past few decades from conventional disease-modifying antirheumatic drugs (cDMARDs) to biological DMARDs (bDMARDs), such as tumor necrosis factor inhibitors (TNFi) and interleukin (IL)-17, Il-23 inhibitors, and small molecules.12 However, new-onset psoriasis or deterioration of the skin involvement in patients with AS, rheumatoid arthritis (RA) or psoriatic arthritis (PsA) have been reported after TNFi treatment.12, 13 This new or flared form of psoriasis is a rare complication of TNFi therapy known as TNFi-associated psoriasis. Harrison et al14 reported an increased incidence of psoriasis in RA patients treated with TNFi, as low as 1/1000 person-years (based on 25 cases). A total of 9826 and 2880 patients from the Registry of Biological Products of the British Society of Rheumatology receiving anti-TNF therapy and DMARD treatment were investigated, and a significantly increased risk of psoriasis in patients treated with adalimumab (incident rate ratio [IRR] 9.6; 95% confidence interval [CI]: 1.2–77.8) was observed compared with the risk of psoriasis in patients treated with etanercept (IRR 4.6; 95% CI: 1.7–12.1) or infliximab (IRR 3.5; 95% CI: 1.3–9.3). Furthermore, Kary et al13 observed that drug discontinuation or dose reduction only resulted in minimal improvement in RA patients. Notably, biologics reduced the severity of symptoms in some patients and affected RA activity; however, determining which biologics resulted in less severe disease was difficult. Recently, Thein et al15 reported hazard ratios (HRs) of 2.12 (95% CI: 1.87–2.40; P < 0.001) and 6.50 (95% CI: 4.60–9.23; P < 0.001) for developing non-pustular and pustular psoriasis, respectively, compared with conventional treatment. Yongdong Zhao et al16 reported an increased incidence of psoriasis in juvenile idiopathic arthritis (JIA) patients treated with TNFi (based on 8225 cases). The HR of new onset of psoriasis after ever exposure to TNFi was 3.02 (95% CI: 2.26 to 4.02, unadjusted) and 2.93 (95% CI: 2.15 to 3.98, adjusted) (P < 0.01). The adjusted HR (95% CI) of psoriasis after TNFi exposure was 1.68 (1.11 to 2.54, P = 0.01) in psoriatic JIA. The risk of new-onset TNFi- associated psoriasis was increased in the non-psoriatic arthritis subset. The adjusted HR (95% CI) of psoriasis after TNFi exposure was 5.60 (3.47 to 9.05, P < 0.01) in the non-psoriatic arthritis subset. In addition, Napolitano et al17 evaluated the incidence of new cases of PsA in patients with plaque psoriasis receiving biologic drugs (based on 327 cases). They found that 22 out of 327 patients with plaque psoriasis developed PsA during treatment with biologic drugs. In particular, 6 (27.2%) PsA patients were under etanercept therapy, 10 (45.4%) under adalimumab, 4 (18.2%) under ustekinumab and 2 (9.2%) under infliximab. Most psoriasis lesions may result from prolonged production of type I interferon, which is caused by inhibiting the maturation of plasmacytoid dendritic cell-dependent TNF. This most often occurs within the first 1.5 years of treatment with TNFi, although it may occur within a week or up to several years after treatment.18, 19 Another possible mechanism is the immune escape phenomenon from Th1 to Th17 reaction in patients with TNF inhibitors.20 In addition, other mechanisms may exist; the effect of TNF-α blockade could conduce to activation of autoreactive T cells in the epidermis which increases keratinocyte proliferation and results in development of psoriasis.21-24 And the TNF-α antagonist could also increase the expression of chemokine receptors, such as CXCR3, which promote infiltration of autoreactive T lymphocytes to the skin.25, 26 In Figure 1, a possible mechanism is illustrated to explain the etiology of the novel form of psoriasis. Clinically, risk factors, prevention, and optimal treatment strategies of TNFi-associated psoriasis remain poorly understood. In general, switching from TNFi to other mechanisms of action which target therapies, such as IL-17 or IL-23, is recommended in patients with TNFi-associated psoriasis. TNFi has become an important choice for patients with rheumatic diseases who cannot tolerate or have inadequate response to traditional therapy. The incidence of TNFi-associated psoriasis is about 1% ~ 5% among patients with RA, 0.7% ~ 5.4% with JIA and 5.8% ~ 6.7% with PsA.16, 17, 27 At present, there are no clear classification criteria for TNFi-associated psoriasis, The actual mechanisms of TNFi-mediated inhibition or trigger of psoriasis remain unknown. These mechanisms may be related to the complexity and variability of the human immune responses and genetic factors. Clinicians should be aware of this association and consider switching to other therapies such as IL-17 or IL-23 or Janus-activated kinase inhibitors. We would like to thank all authors for their contributions. This work was supported by grants from the Guizhou Province Science and Technology Plan Project (Qiankehe Platform Talent [2020] 2202), and Qiankehe Support [2021] General 006. Xue-ming Yao and James Cheng-Chung Wei provided valuable advice on research design and draft papers. Feng Luo and Su-Boon Yong analyzed the data and drafted a paper. Yung-Heng Lee, Wu-kai Ma, revised the paper. James Cheng-Chung Wei is Editor-in-Chief of the journal and co-author of this article. He were excluded from the peer review process and all editorial decisions related to the acceptance and publication of this article.